Literature DB >> 26645629

Binding Interactions of Dopamine and Apomorphine in D2High and D2Low States of Human Dopamine D2 Receptor Using Computational and Experimental Techniques.

Serdar Durdagi1, Ramin Ekhteiari Salmas1,2, Matthias Stein3, Mine Yurtsever2, Philip Seeman4.   

Abstract

We have recently reported G-protein coupled receptor (GPCR) model structures for the active and inactive states of the human dopamine D2 receptor (D2R) using adrenergic crystal structures as templates. Since the therapeutic concentrations of dopamine agonists that suppress the release of prolactin are the same as those that act at the high-affinity state of the D2 receptor (D2High), D2High in the anterior pituitary gland is considered to be the functional state of the receptor. In addition, the therapeutic concentrations of anti-Parkinson drugs are also related to the dissociation constants in the D2High form of the receptor. The discrimination between the high- and low-affinity (D2Low) components of the D2R is not obvious and requires advanced computer-assisted structural biology investigations. Therefore, in this work, the derived D2High and D2Low receptor models (GPCR monomer and dimer three-dimensional structures) are used as drug-binding targets to investigate binding interactions of dopamine and apomorphine. The study reveals a match between the experimental dissociation constants of dopamine and apomorphine at their high- and low-affinity sites of the D2 receptor in monomer and dimer and their calculated dissociation constants. The allosteric receptor-receptor interaction for dopamine D2R dimer is associated with the accessibility of adjacent residues of transmembrane region 4. The measured negative cooperativity between agonist ligand at dopamine D2 receptor is also correctly predicted using the D2R homodimerization model.

Entities:  

Keywords:  D2High and D2Low states of dopamine; Dopamine D2 receptor; GPCR dimerization; molecular docking; protein engineering

Mesh:

Substances:

Year:  2015        PMID: 26645629     DOI: 10.1021/acschemneuro.5b00271

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  7 in total

1.  Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Authors:  Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero
Journal:  Synapse       Date:  2016-07-11       Impact factor: 2.562

2.  The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics.

Authors:  Agnieszka A Kaczor; Manuela Jörg; Ben Capuano
Journal:  J Mol Model       Date:  2016-08-04       Impact factor: 1.810

3.  In vitro and in silico analysis of the effects of D2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations.

Authors:  Wilhelmus E A de Witte; Joost W Versfelt; Maria Kuzikov; Solene Rolland; Victoria Georgi; Philip Gribbon; Sheraz Gul; Dymphy Huntjens; Piet Hein van der Graaf; Meindert Danhof; Amaury Fernández-Montalván; Gesa Witt; Elizabeth C M de Lange
Journal:  Br J Pharmacol       Date:  2018-09-21       Impact factor: 8.739

4.  Integrating Ligand and Target-Driven Based Virtual Screening Approaches With in vitro Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer Assay to Identify Novel Hit Compounds Against BCL-2.

Authors:  Gurbet Tutumlu; Berna Dogan; Timucin Avsar; Muge Didem Orhan; Seyma Calis; Serdar Durdagi
Journal:  Front Chem       Date:  2020-04-09       Impact factor: 5.221

5.  Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study.

Authors:  Kayhan Bolelli; Tugba Ertan-Bolelli; Ozan Unsalan; Cisem Altunayar-Unsalan
Journal:  J Mol Struct       Date:  2020-10-13       Impact factor: 3.196

6.  Identification of Novel Dopamine D2 Receptor Ligands-A Combined In Silico/In Vitro Approach.

Authors:  Lukas Zell; Constanze Lainer; Jakub Kollár; Veronika Temml; Daniela Schuster
Journal:  Molecules       Date:  2022-07-11       Impact factor: 4.927

7.  Transcription factor NF-κB as target for SARS-CoV-2 drug discovery efforts using inflammation-based QSAR screening model.

Authors:  Tarek Kanan; Duaa Kanan; Ebrahim Jaafar Al Shardoub; Serdar Durdagi
Journal:  J Mol Graph Model       Date:  2021-06-23       Impact factor: 2.518

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.